Rico Bio’s B Shingles Vaccine Receives Phase III Clinical Summary Report
Rico Bio’s B shingles vaccine has received a Phase III clinical summary report.
Related stories
Mondelez shares rise 6.4% premarket after Q3 profit beat
M impact | EQUITY | Oct 30, 2026, 08:29 AM UTC
MediaTek CEO Says AI Demand Growth Will Continue
CEO Rick Tsai said AI demand growth will continue, though its rate may vary.
M impact | EQUITY | Oct 30, 2026, 08:26 AM UTC
Xi Says Upgraded China-Switzerland Trade Deal Reflects Shared Commitment
Chinese President Xi Jinping told Switzerland’s federal president that the upgraded trade agreement reflects both countries’ commitment to open cooperation.
M impact | EQUITY | Oct 30, 2026, 08:26 AM UTC
Mondelez Q3 Adjusted Earnings and Revenue Rise
M impact | EQUITY | Oct 30, 2026, 08:25 AM UTC
RBC Analyst Sees Resilient Refining Earnings at BP
RBC Capital Markets analyst Biraj Borkhataria says BP continues to beat expectations, citing strong operational performance and net debt below its target one year early.
M impact | EQUITY | Oct 30, 2026, 08:25 AM UTC
Symbotic Expands Walmart Deal With $6 Billion Initial Spending Commitment
Symbotic announced an expanded commercial agreement with Walmart to extend automation across 25 U.S. regional distribution centers.
H impact | EQUITY | Oct 30, 2026, 08:21 AM UTC